Ex vivo expansion of human CD8 + T cells using autologous CD4 + T cell help

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Butler, Marcus O ^a,b,c   Imataki, Osamu ^a,b,c   Yamashita, Yoshihiro ^d   Tanaka, Makito ^a,b,c   Ansén, Sascha ^a,b,c   Berezovskaya, Alla ^a   Metzler, Genita ^a   Milstein, Matthew I ^a   Mooney, Mary M ^a   Murray, Andrew P ^a   Mano, Hiroyuki ^d,e   Nadler, Lee M ^a,b,c   Hirano, Naoto ^a,b,c,f,g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; OKT 3; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN DERIVATIVE;

ANTIGEN PRESENTING CELL; ARTICLE; ARTIFICIAL CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FEEDER CELL; GENETIC ENGINEERING; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN K 562; COCULTURE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKINS; K562 CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; MUROMONAB-CD3; RECEPTORS, INTERLEUKIN-21; T-LYMPHOCYTES; UP-REGULATION;

EID: 84862927051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030229     Document Type: Article

References (71)

1. Dunn GP, Old LJ, Schreiber RD, (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
2. Pellegrini M, Mak TW, Ohashi PS, (2010) Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends Pharmacol Sci 31: 356-363.
3. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, et al. (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68: 889-892.
4. Parmiani G, De Filippo A, Novellino L, Castelli C, (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178: 1975-1979.
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
6. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, et al. (2004) Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 191: 1598-1605.
7. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, et al. (2005) Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13: 1153-1158.
8. Mihm MC Jr, Clemente CG, Cascinelli N, (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74: 43-47.
9. Mantovani A, Romero P, Palucka AK, Marincola FM, (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
10. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
11. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al. (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902-911.
12. Wilke CM, Wu K, Zhao E, Wang G, Zou W, (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127: 748-758.
13. Shimizu J, Yamazaki S, Sakaguchi S, (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
14. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
15. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593.
16. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, et al. (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
17. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
18. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
19. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, et al. (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24: 5060-5069.
20. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, et al. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377.
21. Berger C, Turtle CJ, Jensen MC, Riddell SR, (2009) Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 21: 224-232.
22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
23. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
24. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271.
25. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, et al. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-22.
26. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115.
27. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
28. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912.
29. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP, (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26: 111-117.
30. Rosenberg SA, Dudley ME, (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
31. Zhou J, Dudley ME, Rosenberg SA, Robbins PF, (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53-62.
32. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130.
33. Muranski P, Restifo NP, (2009) Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21: 200-208.
34. Rochman Y, Spolski R, Leonard WJ, (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480-490.
35. Wilson EB, Livingstone AM, (2008) Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 181: 7445-7448.
36. Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A, (2007) Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol 37: 1502-1512.
37. Williams MA, Tyznik AJ, Bevan MJ, (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890-893.
38. Bevan MJ, (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595-602.
39. Elsaesser H, Sauer K, Brooks DG, (2009) IL-21 is required to control chronic viral infection. Science 324: 1569-1572.
40. Yi JS, Du M, Zajac AJ, (2009) A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572-1576.
41. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, et al. (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576-1580.
42. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, et al. (2008) IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A 105: 5201-5206.
43. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ, (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
44. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
45. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
46. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
47. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, et al. (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13: 1857-1867.
48. Butler MO, Ansen S, Tanaka M, Imataki O, Berezovskaya A, et al. (2010) A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol 22: 863-873.
49. Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, et al. (2006) Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20: 1889-1892.
50. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, et al. (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15: 981-988.
51. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, et al. (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20: 143-148.
52. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA, (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342.
53. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, et al. (2006) Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107: 1528-1536.
54. Prazma CM, Yazawa N, Fujimoto Y, Fujimoto M, Tedder TF, (2007) CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J Immunol 179: 4550-4562.
55. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, et al. (1997) Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 159: 5921-5930.
56. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA, (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250.
57. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, et al. (2004) CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 200: 1407-1417.
58. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, et al. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175: 7046-7052.
59. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, et al. (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176: 7726-7735.
60. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
61. Ridge JP, Di Rosa F, Matzinger P, (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
62. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, et al. (2006) Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 107: 3708-3715.
63. Lee BO, Hartson L, Randall TD, (2003) CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med 198: 1759-1764.
64. Sun JC, Bevan MJ, (2004) Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172: 3385-3389.
65. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8(+) T cells. J Clin Invest 115: 1616-1626.
66. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, et al. (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258-267.
67. Korn T, Bettelli E, Oukka M, Kuchroo VK, (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
68. Li MO, Flavell RA, (2008) Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468-476.
69. Butler M, Friedlander P, Mooney M, Drury L, Metzler M, et al. (2009) Establishing CD8+ T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses. Blood (ASH Annual Meeting Abstracts) 114: 782-.
70. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, et al. (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95: 13141-13146.
71. Andersson AK, Feldmann M, Brennan FM, (2008) Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 68: 103-111.